Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies

IntroductionPembrolizumab has shown clinical benefit in patients with previously treated recurrent or metastatic SCLC in the phase 1b multicohort study KEYNOTE-028 (NCT02054806) and the phase 2 multicohort study KEYNOTE-158 (NCT02628067). We present a pooled analysis of patients from KEYNOTE-028 and KEYNOTE-158 who had received two or more lines of previous therapy for SCLC.MethodsEligible patients were aged 18 years and above, had histologically or cytologically confirmed incurable recurrent or metastatic SCLC, had an Eastern Cooperative Oncology Group performance status of 1 and below, and had received two or more lines of previous therapy. Patients in KEYNOTE-028 were required to have a programmed death ligand 1 (PD-L1)–positive tumor. Patients received pembrolizumab (10 mg/kg every 2 weeks in KEYNOTE-028 or 200 mg every 3 weeks in KEYNOTE-158) for up to 2 years. The primary end point was objective response rate per Response Evaluation Criteria in Solid Tumors version 1.1, which is presented here per independent review.ResultsEighty-three patients who had received two or more lines of previous therapy (KEYNOTE-028, n = 19; KEYNOTE-158, n = 64) were included. Median follow-up duration was 7.7 (range, 0.5–48.7) months. Objective response rate was 19.3% (95% confidence interval: 11.4–29.4); two patients had complete response (one with a PD-L1–positive tumor), and 14 patients had partial response (13 with PD-L1–positive tumors). The median duration of response was not reached (range, 4.1‒35.8+ mo; plus sign indicates ongoing response); 61% of responders had responses lasting 18 months or longer. Fifty-one patients (61.4%) experienced any-grade treatment-related adverse events; eight patients (9.6%) had grade 3 or higher events.ConclusionsPembrolizumab exhibited durable antitumor activity in a subset of patients with recurrent or metastatic SCLC who had undergone two or more previous lines of therapy, regardless of PD-L1 expression. Pembrolizumab was well tolerated.     

Genetic and epigenetic alterations of the EGFR and mutually independent association with BRCA1, MGMT,and RASSF1A methylations in Vietnamese lung adenocarcinomas

Genetic and epigenetic alterations importantly contribute to the pathogenesis of lung cancer. In the study, we measured the frequency and distribution of molecular abnormalities of EGFR as well as the aberrant promoter methylations of BRCA1, MGMT, MLH1, and RASSF1A in Vietnamese lung adenocarcinomas. We investigated the association between genetic and epigenetic alteration, and between each abnormality with clinicopathologic parameters. Somatic EGFR mutation that was found in 49/139 (35.3%) lung adenocarcinomas showed a significant association with young age, female gender, and non-smokers. EGFR overexpression was identified in 82 tumors (59.0%) and statistical relationships with EGFR or BRCA1 methylation but not EGFR mutation. In addition, EGFR, BRCA1, MGMT, MLH1, and RASSF1A methylations were found in 33 (23.7%), 41 (29.5%), 46 (33.1%), 28 (20.1%), and 41 (29.5%) cases of a total of 139 lung adenocarcinomas, respectively. The RASSF1A methylation was found to be linked to the smoking habit. Methylations in MGMT and RASSF1A were also found to correlate with metastasis status. Furthermore, the distribution of EGFR mutation and that of BRCA1, MGMT or RASSF1A methylation were significantly exclusive in lung adenocarcinomas. The main finding of our study demonstrate that epigenetic abnormalities might play a critical role for the lung tumorigenesis in patients with smoking history and metastasis, and partly affect the predictive value of EGFR mutations through blocking expression due to promoter EGFR hypermethylation. Mutually exclusive distribution of genetic and epigenetic alterations reflects differently biological characteristics in the etiology of lung adenocarcinomas.     

miR-9通过靶向E盒结合锌指蛋白2调控小细胞肺癌的恶性生物学行为及其可能的机制

目的：探讨 miR-9 通过靶向 E 盒结合锌指蛋白 2（zinc finger E-box binding homeobox 2，ZEB2）对小细胞肺癌（small cell lung cancer，SCLC）细胞生物学行为的调控作用，分析miR-9在SCLC中的作用及其工作机制。方法：采用qPCR、WB和免疫组化方法检测于2018年2月至2019年11月于河北医科大学第四医院肿瘤内科接受手术治疗的67例SCLC患者癌组织及癌旁组织中ZEB2的表达。采用TargetScan预测miR-9的潜在靶基因并通过双荧光素酶报告基因试验、qPCR和WB法进行验证。CCK-8法、流式细胞术和Transwell实验检测miR-9和ZEB2 过表达对 NCI-H446 的生物学行为影响，WB法检测对细胞中E-cadherin，N-cadherin和Vimentin蛋白表达的影响。利用miR-9过表达NCI-H446细胞构建SCLC裸鼠移植瘤模型，观察miR-9对裸鼠移植瘤生长的影响。结果：SCLC组织中ZEB2的mRNA和蛋白表达水平明显高于癌旁正常组织（P<0.01）。miR-9在ZEB2的3'' UTR上具有潜在的结合位点，与对照组相比，miR-9过表达组NCI-H446细胞中ZEB2的mRNA和蛋白表达水平明显降低（P<0.01），细胞增殖、迁移和侵袭能力均显著下降（P<0.05或P<0.01），促EMT蛋白表达减少，而同时过表达ZEB2能够逆转上述影响。体内实验中，miR-9过表达组移植瘤体积、重量均明显低于对照组（P<0.05或P<0.01）。miR-9组裸鼠肿瘤组织中和ZEB2蛋白的表达均较对照组明显降低（P<0.01）。结论：miR-9通过靶向调控ZEB2从而抑制SCLC细胞的生物学行为以及NCI-H446裸鼠移植瘤的生长。     

MMP-2和TIMP-2在小细胞肺癌患者血清中的表达及其临床意义

目的：探讨基质金属蛋白酶-2（MMP-2）和金属蛋白酶组织抑制因子-2（TIMP-2）在小细胞肺癌（SCLC）中的表达、两者相关性及临床病理意义。方法：采用放射免疫分析检测80例SCLC患者和35例正常人血清中的MMP-2、TIMP-2水平。结果：80例SCLC患者的MMP-2、TIMP-2血清水平明显高于正常对照组（P〈0.01）;广泛期SCLC患者的血清MMP-2和TIMP-2明显高于局限期患者（P〈0.05）。结论：MMP-2和TIMP-2的高表达对SCLC的发生发展均起重要作用,两者表达水平与SCLC的浸润转移及恶性程度有关。     

Decrease of Interleukin-2 secretion is a new independent prognostic factor associated with poor survival in patients with small-cell lung cancer

Background: We have previously shown that suppression of Interleukin-2(IL-2) secretion was mediated by transforming growth factor (TGF) 1secreted by small-cell lung cancer (SCLC) tumor cells. We have also shown thatIL-2 secretion was significantly impaired in patients with SCLC at the timeof diagnosis. Reconstitution of cytokine secretion correlated with reductionof tumor load. These data suggested that the immune system was suppressed bythe tumor. To address the clinical relevance of cytokine suppression in SCLC,we investigated the correlation of the level of IL-2 secretion with survival.Patients and methods: The significance of correlations between singleparameters in the test groups was calculated by using the linear regressionanalysis, the Wilcoxon rank sum test and the exact test according to Fisher.Using the Kaplan–Meier method, the log-rank test and the Cox-regressionmodel, we analysed the relation of IL-2 secretion in whole blood cell culturesfrom 52 patients with SCLC at the time of diagnosis to established prognosticfactors relevant for survival in SCLC.Results: Impairment of IL-2 secretion significantly correlates to survivalin SCLC (P = 0.004). Further univariate and multivariate analysis showed thatthis prognostic factor is independent from other factors of prognosticrelevance in SCLC, namely stage of disease, neurone specific enolase (NSE),lactate dehydrogenase (LDH), age, and sex. More important, the prognosticvalue of IL-2 secretion is comparable to the most predominant prognosticfactors for survival in SCLC identified so far. In the final model of the coxregression analysis, the P-value for IL-2 secretion in relation to stage ofdisease was 0.012 and 0.019, respectively.Conclusions: IL-2 secretion at the time of diagnosis represents anindependent prognostic factor for survival in SCLC. Although its prognosticvalue has to be confirmed in a larger group of patients, our resultsdemonstrate that IL-2 secretion may play an important role in diagnosis andtreatment of SCLC. Moreover, in contrast to other prognostic factors,impairment of IL-2 secretion may help to understand immunosuppression in SCLCand, thus, important elements of the pathogenesis of this disease.     

Outcome of combination chemotherapy in extensive stage small-cell lung cancer: Any treatment related progress?

During the past two decades many different treatment regimens of combination chemotherapy have been applied in extensive stage small-cell lung cancer (SCLC). This study was carried out to identify whether these modifications have resulted in an improved overall survival for extensive stage during the past two decades. In total, 1111 patients with extensive stage SCLC were included in six consecutive randomised trials in our setting from 1973 until 1992. Of these, 526 patients treated in the early period (1973–1981) were compared with 585 patients treated in the late period (1981–1992) with respect to pretreatment prognostic factors, staging, treatment and outcome. No change in the distribution of prognostic factors was detected and the frequency of patients with extensive stage was equal in the two periods, and no difference in overall response rates and survival was observed (P=0.49). Median survival in the two periods was 208 days and 215 days, respectively. No stage migration or treatment-related improved outcome was observed in extensive disease. We suggest restricting aggressive treatment to patients with favorable prognosis and long-term survival as a realistic aim.     

c-Kit蛋白在小细胞肺癌中的表达及临床病理意义

目的:探讨c-Kit蛋白的表达与小细胞肺癌(SCLC)发生、发展的关系.方法:应用免疫组化SABC法检测65例手术切除SCLC、癌旁组织和正常肺组织中,c-Kit蛋白的表达.结果:SCLC中c-Kit蛋白阳性表达率明显高于正常肺组织和癌旁组织(P《0.05).c-Kit蛋白的表达与肿瘤大小以及预后生存期密切相关(P《0.05).与SCLC患者性别、年龄、淋巴结转移情况无明显相关(P》0.05).结论:c-Kit蛋白的表达与SCLC的发生、发展及肿瘤大小及预后密切相关.     

Ultra-micro samples can be used for mRNA quantification of lung cancer biomarkers

Background Isolating sufficient material for molecular testing remains challenging in non-small cell lung cancer (NSCLC). The use of new ultra-microsamples (uMS) is proven sufficient for DNA and mRNA detection, but whether uMS are useful for quantifying mRNA expression is unknown. We investigated if uMS from lung cancer patients can be used to generate quantitative data on mRNA expression. Methods uMS were collected from primary tumors and lymph nodes from patients suspected of having lung cancer. mRNA was isolated, reverse-transcribed into cDNA and quantified with quantitative PCR assays for hepatocyte growth factor receptor (MET), hepatocyte growth factor (HGF), epidermal growth factor receptor (EGFR) and amphiregulin (AREG) mRNA. The fraction of tumor cells to normal cells was estimated in each sample. Results MET, HGF, EGFR, and AREG expression were evaluated in 90 samples (30 containing cancer cells and 60 without cancer cells). MET and EGFR expression were negligible in samples without cancer cells. In samples containing cancer cells, MET and EGFR could be quantified in 13 samples each. Adjustment for tumor-cell fraction made it possible to obtain a quantitative result for the tumor-cell mRNA expression of MET and EGFR. In contrast, AREG and HGF were expressed in samples without tumor cells. These samples were used to establish the AREG and HGF mRNA expression in normal cells. Seven out of 14?AR-positive and two out of eight HGF-positive samples with tumor cells were above a cut-off of the mean?+?2SD established in samples without tumor cells. Conclusion We demonstrate that uMS contain high-quality mRNA, and quantitative studies can be performed when the tumor-cell fraction is considered.